BPC-157 + TB-500 for Injury Recovery

Most injuries stall because the tissue can't get what it needs. Blood flow is restricted, inflammatory signals persist, and the repair machinery sits idle. BPC-157 and TB-500 address this directly: BPC-157 restores microcirculation while TB-500 mobilizes the cells that actually rebuild tissue.

This combination—sometimes called the "Wolverine Stack"—is commonly used in the first 4–8 weeks of injury recovery to establish the vascular and cellular foundation that all later healing depends on.

At a Glance

Cycle length: 6–10 weeks (TB-500), 8–12 weeks (BPC-157)

Bottom line: BPC-157 builds the vascular roads; TB-500 directs the repair cells traveling on them.

Who This Is For

People with tendon, ligament, or soft tissue injuries who want:

• A simpler protocol focused on the two most critical repair bottlenecks
• Clear structure without managing five compounds
• A foundation that can be expanded if needed

This stack addresses vascular access and cellular mobility—the layers most injuries need first. For more complex or chronic injuries, the 5-compound protocol adds energy, collagen quality, and inflammation control.

Why These Two Together

After injury, the body's first reaction is containment: vessels constrict, platelets form clots, and inflammatory cells flood the site. That emergency response stops bleeding but also chokes micro-circulation, leaving the region hypoxic and energy-starved. Unless new capillaries grow and fibroblasts start moving again, healing stalls in the inflammatory phase.

This is the "half-healed" state many people know too well:

• Pain that waxes and wanes
• Stiffness that never fully resolves
• Tissue that feels both tight and weak
• Morning mobility that takes 20+ minutes to return

How They Work

Synergy

Together they shift tissue from M1 macrophages (inflammatory mode) to M2 (repair mode) without the collateral effects of NSAIDs or steroids.

Dosing Protocol

Cycle length: 6–10 weeks (TB-500), 8–12 weeks (BPC-157)

Weight-Based Guidance

• BPC-157: ~6–8 mcg/kg daily
• TB-500: ~0.04–0.06 mg/kg per dose

Weekly Schedule (Example)

Adjust based on your schedule. Consistency matters more than specific days.

Timeline: What to Expect

Days 3–7

Weeks 1–2

Weeks 2–4

Weeks 4–8

Most people notice reduced pain and improved warmth within the first 1–2 weeks. Functional improvements (load tolerance, mobility) typically develop over weeks 3–4.

Supporting Factors

Movement matters: Static rest delays organized healing—the new collagen needs directional stress signals.

When Progress Stalls

Managing Side Effects

Contraindications

Do not use if:

• Active cancer or malignancy within 2 years (both peptides promote angiogenesis)
• Pregnancy or breastfeeding
• Proliferative retinopathy
• Surgery planned or recent (<2 weeks)

Use with medical supervision if:

• Concurrent corticosteroid use (steroids oppose tissue repair mechanisms)
• Severe cardiovascular disease
• Active autoimmune conditions
• Therapeutic anticoagulation

Sports compliance: TB-500 is prohibited by WADA/USADA.

What Comes Next

After 6–8 weeks, assess:

Complete: If markers are met (pain ≤2/10, ROM ≥80%, no edema after activity, tissue warm and supple), taper off. Many clinicians recommend 2–4 week taper rather than abrupt stop.

Extend: If progress is good but incomplete, continue for another 4 weeks.

Upgrade: If specific bottlenecks persist, move to the 5-compound protocol or add individual compounds:

• Energy issues → NAD+
• Collagen quality → GHK-Cu
• Inflammation → KPV

For chronic injuries with sleep disruption, see Tesamorelin for Injury Recovery. For neuropathic symptoms, see ARA-290 for Nerve Pain.

Storage and Handling

• Reconstitute with bacteriostatic water under clean technique
• Refrigerate at 2–8°C after reconstitution; protect from light
• Beyond-use: 2–4 weeks refrigerated
• BPC-157 and TB-500 can be co-injected (pH compatible)

FAQ

Can I combine BPC-157 and TB-500 in one syringe?

Yes, they're pH compatible. Many clinicians co-inject without issues. If you're unsure about stability, use separate syringes. Avoid mixing either with acidic peptides like NAD+.

What if I'm still in a brace or boot?

Start with systemic injections (abdomen/thigh). Once cleared to move, shift BPC-157 closer to the injury site. Immobilization doesn't prevent peptide benefit, but collagen alignment will be less organized without directional stress.

Should I stop physical therapy?

No. These peptides support PT—they restore blood flow, which makes rehab exercises more effective. The peptides provide the infrastructure; PT provides the directional stress signals for organized collagen.

How long until I feel something?

Most people notice reduced pain and improved warmth within the first 1–2 weeks. Functional improvements (load tolerance, mobility) typically develop over weeks 3–4. If you feel nothing by week 3, reassess injection technique, storage conditions, or discuss dosing with your clinician.

Is local injection really better than systemic?

For tendon/ligament injuries, local injection (1–2 cm from the injury site) typically produces faster, more targeted results. However, systemic injection still works—both peptides reach target tissues through circulation. If local injection is impractical or uncomfortable, systemic is a valid approach.

Can I take NSAIDs while using these peptides?

Avoid if possible. NSAIDs suppress the inflammatory phase of healing, which can interfere with the signals these peptides are trying to restore. If you must use NSAIDs for acute pain, use the lowest effective dose for the shortest duration.

What about corticosteroid injections?

Corticosteroids and repair peptides work against each other. Steroids suppress fibroblast proliferation and angiogenesis—exactly what BPC-157 and TB-500 are trying to promote. If you've had a recent steroid injection, wait 2–4 weeks before starting peptide therapy.

How do I know if the peptides are working?

Early signs (week 1–2): Warmth returning to the area, reduced sharp pain, less morning stiffness.

Later signs (week 3–4): Improved pliability, better tolerance of gentle loading, ROM improvements, less reactivity after activity.

What's the difference between TB-500 and TB-4?

TB-500 is supposed to be thymosin β4 fragment 17–23—a small, 7-amino-acid active fragment (~800 Da molecular weight).

TB-4 is the full-length 43-amino-acid thymosin β4 protein (~4,900 Da molecular weight).

The problem: Most vendors selling "TB-500" are actually selling full TB-4. The fragment is harder to synthesize and less commercially available. Both have tissue repair activity, but they're not the same compound.

How do I know if I have real TB-500 or TB-4?

Check the Certificate of Analysis (COA) or third-party lab report:

If the COA shows molecular weight around 4,900 Da or lists 43 amino acids, you have TB-4, not TB-500—regardless of what the label says.

Does it matter? Both work for tissue repair. TB-4 is the parent molecule; the fragment contains the active region. Most clinical and research literature uses TB-4. The main issue is knowing what you're actually using for dosing purposes.

Should I continue after the injury feels healed?

Many clinicians recommend a 2–4 week taper rather than abrupt cessation. During taper, reduce TB-500 frequency first (once weekly), then BPC-157 (every other day). This allows collagen remodeling to consolidate.

What if pain increases during the first week?

Mild increases in awareness or dull aching can occur as blood flow returns—this is the "warming up" effect. However, if pain increases significantly (>4/10) or changes character (becomes sharp, burning, or shooting), pause and consult your clinician.

Can I use these for chronic injuries (6+ months old)?

Yes, but expectations should be realistic. Chronic injuries often have multiple bottlenecks beyond vascular access. BPC-157 + TB-500 address the foundational layers. Complete chronic injury resolution often requires the 5-compound protocol or add-on modules.

Are there long-term risks?

Human long-term safety data is limited. The primary theoretical concern is promoting angiogenesis in contexts where it's harmful (occult malignancy, proliferative retinopathy). For healthy individuals without these conditions, no significant long-term adverse effects have been identified. Most practitioners use defined cycles rather than indefinite use.

Related Guides

• 5-Compound Protocol — Complete protocol with NAD+, GHK-Cu, KPV
• Tesamorelin for Injury Recovery — GH timing and sleep-timed repair
• ARA-290 for Nerve Pain — Small-fiber nerve support
• SS-31 Add-On — Mitochondrial stability
• Complete BPC-157 Guide — Deep dive on BPC-157
• NAD+ Guide — Cellular energy

References

• BPC-157 review: PMC8275860
• TB-500 dermal repair: PubMed 12581423
• TB-500 fragment context: PMC7822313

This content is for educational purposes only. BPC-157 and TB-500 are not FDA-approved medications. Peptide therapy requires medical supervision. Consult a qualified healthcare provider before starting any protocol.